GET DAILY SIGNALSPrecision Optics (POCI) Consolidates Near $4.86 Following a Modest +4% Monthly Advance
Key Takeaways
- Precision Optics Corporation (NASDAQ: POCI) traded near $4.86, up roughly 4% over the trailing 30 days, a modest move that keeps the stock in a range-bound consolidation.
- The company designs and manufactures advanced micro-optics and imaging systems for medical device and defense/aerospace customers, with a growing satellite laser-communications vertical.
- Fiscal 2026 revenue rose approximately 65% to $31.5 million, and the company posted two consecutive quarters of positive adjusted EBITDA.
- A $2 million satellite optical-communications follow-on order announced in November signaled renewed demand momentum after a temporary customer slowdown.
- Fiscal 2027 guidance calls for roughly flat revenue as an existing satellite customer temporarily pauses orders, partially offset by growth in medical and defense programs.
Where POCI Stands in Today’s Market
Precision Optics Corporation trades on the Nasdaq under the ticker POCI, with a market capitalization of roughly $53 million. The stock has been consolidating in the mid-$4 range, with its 52-week range spanning approximately $3.55 to $6.15. Over the trailing 30 days, shares moved modestly higher—from around $4.67 to about $4.86—representing a gain of approximately 4%, a level consistent with a low-beta, small-cap name rather than a sharp directional move.
Investor sentiment has been shaped by the company's transition from engineering-led development work toward higher-volume production, as well as by the temporary pause in orders from its largest satellite communications customer. The broader positioning reflects both the company's demonstrated manufacturing scale-up and lingering questions about near-term revenue visibility. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Business Overview and Competitive Edge
Founded in 1982 and headquartered in Littleton, Massachusetts, Precision Optics is a vertically integrated optics company focused on micro-optics, 3D imaging, and digital imaging technologies. Its business spans two primary segments: medical devices and defense/aerospace, with an increasingly important satellite communications vertical.
On the medical side, the company supplies micro-endoscopes, endocouplers, single-use and reusable endoscopes, and imaging assemblies used in minimally invasive and robotic surgery. Its Ross Optical division adds global sourcing, inspection, and high-volume production of custom and catalog optics. In defense and aerospace, Precision Optics applies its micro-optics and opto-mechanical expertise to applications that require optimized size, weight, and power—including precision subassemblies for satellite laser-communications terminals.
A key competitive strength is the company's ability to hold extremely tight alignment tolerances, as fine as five microns, which is a demanding requirement for laser-based satellite-to-satellite communication. This capability, combined with demonstrated production yields that reached 99% in its most recent quarter, positions Precision Optics as a specialized supplier in a fast-growing but technically difficult market.
Recent Developments and Momentum
In late September, Precision Optics reported record fiscal fourth-quarter revenue of $8.8 million, up about 42% year over year, and full-year fiscal 2026 revenue of $31.5 million, an increase of approximately 65%. Gross margin in the fourth quarter improved to 25.3% from 13.0% a year earlier, and adjusted EBITDA turned positive for a second consecutive quarter.
In November, the company announced a $2 million follow-on production order from an existing top-tier aerospace customer for its established satellite optical communications program, with shipments expected to begin in December. Management described the order as arriving ahead of expectations and reinforcing confidence in the program's recovery.
At the same time, the company is managing a temporary pause in demand from its primary satellite customer, which stems from constrained satellite launch capacity rather than any loss of the underlying relationship. To offset this, Precision Optics has secured initial engineering orders from a second satellite communications customer and continues to ramp its single-use ophthalmic and cystoscopy programs.
Fiscal 2027 Guidance and Areas to Monitor
For fiscal 2027, Precision Optics guided revenue to a range of $30 million to $33 million, roughly flat with fiscal 2026, and adjusted EBITDA between negative $1.2 million and negative $1.7 million, an improvement from the prior year. Management expects quarterly losses early in the fiscal year before returning to profitability as the existing satellite customer resumes orders and new programs enter production.
Key factors to monitor include the timing of the satellite customer's order resumption, the progression of the second satellite customer from engineering to production, and continued yield and throughput gains across single-use medical device lines. The next quarterly earnings report and any updates to guidance will be important signals. Broader considerations include supply chain and tariff dynamics, customer concentration risk, and the company's path toward sustained positive adjusted EBITDA. As always, these are factors to observe rather than predictions of future performance. From what I see, the order recovery timeline will be especially telling.
Using Tickeron’s AI Daily Buy/Sell Signals
I often turn to Tickeron’s AI Daily Buy/Sell Signals when evaluating names like this one, as the platform helps surface patterns across thousands of tickers and provides a structured way to compare signals in real time. It has become a regular part of my process for spotting potential entry or exit points without replacing my own fundamental review.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
POCI's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for POCI turned positive on October 29, 2026. Looking at past instances where POCI's MACD turned positive, the stock continued to rise in 42 of 55 cases over the following month. The odds of a continued upward trend are 76%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 29, 2026. You may want to consider a long position or call options on POCI as a result. In 91 of 128 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 71%.
POCI moved above its 50-day moving average on October 29, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for POCI crossed bullishly above the 50-day moving average on November 02, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 19 of 27 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 70%.
Following a +5.77% 3-day Advance, the price is estimated to grow further. Considering data from situations where POCI advanced for three days, in 111 of 163 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.
The Aroon Indicator entered an Uptrend today. In 104 of 152 cases where POCI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 68%.
Bearish Trend Analysis
The 10-day RSI Indicator for POCI moved out of overbought territory on November 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 20 similar instances where the indicator moved out of overbought territory. In 18 of the 20 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where POCI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 76%.
POCI broke above its upper Bollinger Band on October 30, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 20 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.614) is normal, around the industry mean (4.955). P/E Ratio (-11.302) is within average values for comparable stocks, (40.806). Projected Growth (PEG Ratio) (0.110) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (1.113) is also within normal values, averaging (56.876).
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. POCI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 45 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 62 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. POCI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry PharmaceuticalsOther
Advertisement